Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEN1029 Safety Trial in Advanced Solid Tumors
NCT03576131Phase 2Terminated
- Sponsor
- Genmab
- Start
- Apr 2018
- Primary completion
- Oct 2021
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of benufutamab in colorectal cancer (CRC), non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), renal cell carcinoma (RCC), gastric cancer (GC), sponsored by Genmab. Started Apr 2018; status: terminated.
02
Drugs
benufutamab
03
Conditions
colorectal cancer (CRC)non-small cell lung cancer (NSCLC)triple-negative breast cancer (TNBC)renal cell carcinoma (RCC)gastric cancer (GC)
Beyond the preview
Go deeper on NCT03576131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03576131.